• Molecular NameAzimilide
  • SynonymNA
  • Weight457.962
  • Drugbank_IDN/A
  • ACS_NON/A
  • Show 2D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)3.93
  • pkaN/A
  • LogD (pH=7, predicted)2.7
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-2.97
  • LogSw (predicted, AB/LogsW2.0)0.08
  • Sw (mg/ml) (predicted, ACD/Labs)0.05
  • No.of HBond Donors0
  • No.of HBond Acceptors8
  • No.of Rotatable Bonds8
  • TPSA72.6
  • StatusClinical trial
  • AdministrationN/A
  • PharmacologyA class III antiarrhythmic drug (used to control abnormal heart rhythms). The agents from this heterogeneous group have an effect on the repolarization, they prolong the duration of the action potential and the refractory period. Also they slow down the spontaneous discharge frequency of automatic pacemakers by depressing the slope of diastolic depolarization.
  • Absorption_valueN/A
  • Absorption (description)100
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • Metabollsm30% will cleared by cleavage; 25% by CYP 1A1 pathway; 25% by CYP 3A4
  • Half lifeN/A
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A